大分割调强放疗联合阿帕替尼治疗合并上腔静脉综合征非小细胞肺癌老年患者临床研究  

Clinical study of large fraction intensity modulated radiation therapy combined with apatinib in treatment of elderly non-small cell lung cancer patients with superior vena cava syndrome

作　　者：张涛[1] 徐海亭[1] 王强[1] 惠华[1] 丁曼华[1] 许晶[1] 卢志伟 Zhang Tao;Xu Haiting;Wang Qiang;Hui Hua;Ding Manhua;Xu Jing;Lu Zhiwei(Department of Radiation Therapy, Xuzhou Cancer Hospital Affiliated to Jiangsu University, Xuzhou 221000, China)

机构地区：[1]江苏大学附属徐州医院放疗科,221000

出　　处：《肿瘤研究与临床》2019年第5期320-323,共4页Cancer Research and Clinic

摘　　要：目的观察大分割调强放疗联合阿帕替尼治疗合并上腔静脉综合征老年非小细胞肺癌(NSCLC)患者的临床疗效。方法回顾性分析江苏大学附属徐州医院2015年2月至2017年12月收治的合并上腔静脉综合征的老年NSCLC患者46例,分为观察组与对照组(各23例)。对照组行单纯大分割放疗,观察组放疗第1天开始同步口服阿帕替尼,比较两组疗效及不良反应。结果观察组治疗1周完全缓解率为78.3%(18/23),高于对照组的43.3%(10/23)(χ^2=4.60,P<0.05)。观察组有效率为86.9%(21/23),高于对照组的65.2%(15/23)(χ^2=4.294,P<0.05)。两组主要不良反应为放射性食管炎、放射性肺炎、白细胞下降,多数为Ⅰ~Ⅱ级,两组不良反应发生率差异均无统计学意义(均P>0.05)。观察组1年总生存率为56%,对照组为40%,两组差异有统计学意义(P=0.009)。结论大分割调强放疗联合阿帕替尼治疗合并上腔静脉综合征老年NSCLC患者有效,且治疗耐受性良好。To observe the clinical efficacy of large fraction intensity modulated radiation therapy combined with apatinib in the treatment of elderly patients with non-small cell lung cancer and superior vena cava syndrome. Methods A retrospective analysis was made on 46 elderly patients with non-small cell lung cancer and superior vena cava syndrome who were admitted to Xuzhou Cancer Hospital Affiliated to Jiangsu University from February 2015 to December 2017. The patients were divided into observation group and control group with 23 cases in each group. The control group received radiation therapy only. Apatinib was enrolled in the observation group on the first day synchronously. The remission time of symptoms, short-term efficacy, occurrence of adverse reactions and 1-year overall survival rate were observed and compared between the two groups. Results The complete remission rate was 78.3%(18/23) in the observation group and 43.3%(10/23) in the control group, and the difference between the two groups was statistically significant (χ^2= 4.60, P < 0.05). The effective response rate was 86.9%(21/23) in the observation group and 65.2%(15/23) in the control group, and the difference between the two groups was statistically significant (χ^2= 4.294, P < 0.05). The main adverse reactions in the two groups were radioactive esophagitis, radiation pneumonitis and leukopenia, and most of them were grade Ⅰ-Ⅱ, there was no significant difference between the two groups (all P > 0.05). The 1-year overall survival rate was 56% in the observation group and 40% in the control group, and the difference between the two groups was statistically significant (P= 0.009). Conclusion Large fraction intensity modulated radiation therapy combined with apatinib is effective in the treatment of elderly patients with non-small cell lung cancer and superior vena cava syndrome, and the adverse reactions are well tolerated.

关 键 词：癌 非小细胞肺 大分割放疗 阿帕替尼 上腔静脉综合征 

分 类 号：R734.2[医药卫生—肿瘤]